Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sitari Pharmaceuticals
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Sitari Pharmaceuticals was a preclinical biotech developing small-molecule inhibitors of transglutaminase 2 for celiac disease; it advanced a lead program to lead declaration and toward clinical candidate selection before being acquired by GSK, which later took the asset GSK3915393 into early clinical development and then discontinued development for celiac disease.[1][3][5][6][9][15]
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Avalon VenturesGSKCOI PharmaceuticalsStanford University
Beyond the preview
Go deeper on Sitari Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sitari Pharmaceuticals.